Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3923357 | European Urology | 2007 | 9 Pages |
Abstract
The synergy of IFN-α and 5-FU requires p53 activity, suggesting that p53 status may serve as a predictive factor for response to the combination therapy. Because metastatic RCC frequently has p53 mutations, therapy restoring p53 may markedly improve the response rate of immunochemical therapy combining IFN-α and 5-FU.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Donghao Shang, Noriyuki Ito, Jun Watanabe, Yasuo Awakura, Hiroyuki Nishiyama, Toshiyuki Kamoto, Osamu Ogawa,